Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis

Nathalie Pamir, Timothy S. McMillen, Yu I. Li, Ching Mei Lai, Howard Wong, Renée C. LeBoeuf

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Apolipoprotein A5 (APOA5) is expressed primarily in the liver and modulates plasma triglyceride levels in mice and humans. Mice overexpressing APOA5 exhibit reduced plasma triglyceride levels. Because there is a tight association between plasma triglyceride concentration and traits of the metabolic syndrome, we used transgenic mice overexpressing human APOA5 to test the concept that these mice would be protected from diet-induced obesity and insulin resistance. Male and female transgenic and wild-type mice on the FVB/N genetic background were fed standard rodent chow or a diet rich in fat and sucrose for 18 weeks, during which time clinical phenotypes associated with obesity and glucose homeostasis were measured. We found that APOA5 transgenic (A5tg) mice were resistant to diet-induced changes in plasma triglyceride but not total cholesterol levels. Body weights were similar between the genotypes for females and males, although male A5tg mice showed a modest but significant increase in the relative size of inguinal fat pads. Although male A5tg mice showed a significantly increased ratio of plasma glucose to insulin, profiles of glucose clearance as evaluated after injections of glucose or insulin failed to reveal any differences between genotypes. Overall, our data showed that there was no advantage to responses to diet-induced obesity with chronic reduction of plasma triglyceride levels as mediated by overexpression of APOA5.

Original languageEnglish (US)
Pages (from-to)560-567
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume58
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Apolipoproteins
Weight Gain
Homeostasis
Transgenic Mice
Body Weight
Triglycerides
Glucose
Diet
Obesity
Genotype
Insulin
Groin
Sucrose
Insulin Resistance
Adipose Tissue
Rodentia
Fats
Cholesterol
Phenotype
Injections

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis. / Pamir, Nathalie; McMillen, Timothy S.; Li, Yu I.; Lai, Ching Mei; Wong, Howard; LeBoeuf, Renée C.

In: Metabolism: Clinical and Experimental, Vol. 58, No. 4, 04.2009, p. 560-567.

Research output: Contribution to journalArticle

Pamir, Nathalie ; McMillen, Timothy S. ; Li, Yu I. ; Lai, Ching Mei ; Wong, Howard ; LeBoeuf, Renée C. / Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis. In: Metabolism: Clinical and Experimental. 2009 ; Vol. 58, No. 4. pp. 560-567.
@article{b8c9dee414fe476fa47dfe813f2bdc81,
title = "Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis",
abstract = "Apolipoprotein A5 (APOA5) is expressed primarily in the liver and modulates plasma triglyceride levels in mice and humans. Mice overexpressing APOA5 exhibit reduced plasma triglyceride levels. Because there is a tight association between plasma triglyceride concentration and traits of the metabolic syndrome, we used transgenic mice overexpressing human APOA5 to test the concept that these mice would be protected from diet-induced obesity and insulin resistance. Male and female transgenic and wild-type mice on the FVB/N genetic background were fed standard rodent chow or a diet rich in fat and sucrose for 18 weeks, during which time clinical phenotypes associated with obesity and glucose homeostasis were measured. We found that APOA5 transgenic (A5tg) mice were resistant to diet-induced changes in plasma triglyceride but not total cholesterol levels. Body weights were similar between the genotypes for females and males, although male A5tg mice showed a modest but significant increase in the relative size of inguinal fat pads. Although male A5tg mice showed a significantly increased ratio of plasma glucose to insulin, profiles of glucose clearance as evaluated after injections of glucose or insulin failed to reveal any differences between genotypes. Overall, our data showed that there was no advantage to responses to diet-induced obesity with chronic reduction of plasma triglyceride levels as mediated by overexpression of APOA5.",
author = "Nathalie Pamir and McMillen, {Timothy S.} and Li, {Yu I.} and Lai, {Ching Mei} and Howard Wong and LeBoeuf, {Ren{\'e}e C.}",
year = "2009",
month = "4",
doi = "10.1016/j.metabol.2008.11.018",
language = "English (US)",
volume = "58",
pages = "560--567",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis

AU - Pamir, Nathalie

AU - McMillen, Timothy S.

AU - Li, Yu I.

AU - Lai, Ching Mei

AU - Wong, Howard

AU - LeBoeuf, Renée C.

PY - 2009/4

Y1 - 2009/4

N2 - Apolipoprotein A5 (APOA5) is expressed primarily in the liver and modulates plasma triglyceride levels in mice and humans. Mice overexpressing APOA5 exhibit reduced plasma triglyceride levels. Because there is a tight association between plasma triglyceride concentration and traits of the metabolic syndrome, we used transgenic mice overexpressing human APOA5 to test the concept that these mice would be protected from diet-induced obesity and insulin resistance. Male and female transgenic and wild-type mice on the FVB/N genetic background were fed standard rodent chow or a diet rich in fat and sucrose for 18 weeks, during which time clinical phenotypes associated with obesity and glucose homeostasis were measured. We found that APOA5 transgenic (A5tg) mice were resistant to diet-induced changes in plasma triglyceride but not total cholesterol levels. Body weights were similar between the genotypes for females and males, although male A5tg mice showed a modest but significant increase in the relative size of inguinal fat pads. Although male A5tg mice showed a significantly increased ratio of plasma glucose to insulin, profiles of glucose clearance as evaluated after injections of glucose or insulin failed to reveal any differences between genotypes. Overall, our data showed that there was no advantage to responses to diet-induced obesity with chronic reduction of plasma triglyceride levels as mediated by overexpression of APOA5.

AB - Apolipoprotein A5 (APOA5) is expressed primarily in the liver and modulates plasma triglyceride levels in mice and humans. Mice overexpressing APOA5 exhibit reduced plasma triglyceride levels. Because there is a tight association between plasma triglyceride concentration and traits of the metabolic syndrome, we used transgenic mice overexpressing human APOA5 to test the concept that these mice would be protected from diet-induced obesity and insulin resistance. Male and female transgenic and wild-type mice on the FVB/N genetic background were fed standard rodent chow or a diet rich in fat and sucrose for 18 weeks, during which time clinical phenotypes associated with obesity and glucose homeostasis were measured. We found that APOA5 transgenic (A5tg) mice were resistant to diet-induced changes in plasma triglyceride but not total cholesterol levels. Body weights were similar between the genotypes for females and males, although male A5tg mice showed a modest but significant increase in the relative size of inguinal fat pads. Although male A5tg mice showed a significantly increased ratio of plasma glucose to insulin, profiles of glucose clearance as evaluated after injections of glucose or insulin failed to reveal any differences between genotypes. Overall, our data showed that there was no advantage to responses to diet-induced obesity with chronic reduction of plasma triglyceride levels as mediated by overexpression of APOA5.

UR - http://www.scopus.com/inward/record.url?scp=62349138735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349138735&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2008.11.018

DO - 10.1016/j.metabol.2008.11.018

M3 - Article

C2 - 19303979

AN - SCOPUS:62349138735

VL - 58

SP - 560

EP - 567

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4

ER -